Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE
CDZR123A12107
Phase 2 small_molecule active
Quick answer
Luxdegalutamide, DZR123, -, -, DOCETAXEL, CABAZITAXEL, ABIRATERONE, DZR123, ENZALUTAMIDE for Metastatic castrate resistant prostate cancer (mCRPC) is a Phase 2 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Metastatic castrate resistant prostate cancer (mCRPC)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active